journal article·2025-01-29

Promising Nanoparticles-Based Oral Therapy for Effective Inhibition of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Xiangjun Chen, Lu Li, Qing Fan, Lingyu Zhang, Wenting Li, Wei Hong, Chungang Wang, Xiuping Zhang

Nano Letters· Volume 25· Issue 4
Publisher page

Abstract

Portal vein tumor thrombus (PVTT) is a poor prognostic factor for hepatocellular carcinoma (HCC) patients, highlighting the need for an oral drug delivery system that combines convenience, simplicity, biosafety, and improved patient compliance. Leveraging the unique anatomy of the portal vein and insights from single-cell RNA sequencing of the PVTT tumor microenvironment, we developed oral pellets using CaCO 3 @PDA nanoparticles (NPs) encapsulating both doxorubicin hydrochloride and low molecular weight heparin. These NPs target the tumor thrombus microenvironment, aiming to break down the thrombus barrier and turn the challenge of portal vein blockage into an advantage by enhancing drug delivery efficiency through oral administration. The NPs-based oral delivery system achieved excellent antitumor effects with minimal side effects, demonstrating a promising strategy for managing PVTT in advanced HCC and addressing tumor types associated with vascular invasion and hypercoagulability.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Cancer, Hypoxia, and Metabolism · Endoplasmic Reticulum Stress and Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Shandong New Drug Loading & Release Technology and Preparation Engineering Laboratory, Binzhou Medical University, 346 Guanhai Road, Yantai 264003, P. R. China

Department of Chemistry, Northeast Normal University, 5268 Renmin Street, Changchun, Jilin 130024, P. R. China

Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing 100853, P. R. China

Funding

China Association for Science and Technology · Taishan Scholar Project of Shandong Province · Beijing Association for Science and Technology · National Natural Science Foundation of China · Beijing Nova Program · Provincial-level leading talent sponsorship program by Yantai

References (36)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1016/S0140-6736(18)30010-210.1016/S0140-6736(18)30010-2 ↗
3. 10.1002/hep.3232310.1002/hep.32323 ↗
4. 10.3390/cancers1416402810.3390/cancers14164028 ↗
5. 10.1111/hepr.1270510.1111/hepr.12705 ↗
6. 10.1016/S2468-1253(19)30178-510.1016/S2468-1253(19)30178-5 ↗
7. 10.1056/NEJMoa171700210.1056/NEJMoa1717002 ↗
8. 10.1002/hep.3049010.1002/hep.30490 ↗
9. 10.1038/s41571-021-00573-210.1038/s41571-021-00573-2 ↗
10. 10.1097/MCG.000000000000082510.1097/MCG.0000000000000825 ↗
11. 10.14218/JCTH.2021.0017910.14218/JCTH.2021.00179 ↗
12. 10.3389/fonc.2021.69707310.3389/fonc.2021.697073 ↗
13. 10.1245/s10434-019-07504-710.1245/s10434-019-07504-7 ↗
14. 10.1186/s12943-019-0974-610.1186/s12943-019-0974-6 ↗
15. 10.1038/s41551-020-0573-210.1038/s41551-020-0573-2 ↗
16. 10.1016/j.nantod.2023.10178710.1016/j.nantod.2023.101787 ↗
17. 10.1016/j.biomaterials.2020.12054110.1016/j.biomaterials.2020.120541 ↗
18. 10.3390/molecules2820700410.3390/molecules28207004 ↗
19. 10.1016/j.nantod.2023.10204810.1016/j.nantod.2023.102048 ↗
20. 10.1016/j.jconrel.2022.09.04310.1016/j.jconrel.2022.09.043 ↗
21. 10.1021/acs.nanolett.7b0532310.1021/acs.nanolett.7b05323 ↗
22. 10.1016/j.biomaterials.2014.10.05910.1016/j.biomaterials.2014.10.059 ↗
23. 10.1021/jacs.5b0997410.1021/jacs.5b09974 ↗
24. 10.1039/C5BM00056D10.1039/C5BM00056D ↗
25. 10.1039/C9NR03802G10.1039/C9NR03802G ↗
26. 10.1016/j.ijpharm.2020.11976310.1016/j.ijpharm.2020.119763 ↗
27. 10.1021/bm400406x10.1021/bm400406x ↗
28. 10.1016/j.carbpol.2019.11512610.1016/j.carbpol.2019.115126 ↗
29. 10.1016/j.ijpharm.2017.04.07210.1016/j.ijpharm.2017.04.072 ↗
30. 10.3390/polym1411218110.3390/polym14112181 ↗
31. 10.1016/j.biomaterials.2011.03.05610.1016/j.biomaterials.2011.03.056 ↗
32. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
33. 10.1021/acs.nanolett.3c0514610.1021/acs.nanolett.3c05146 ↗
34. 10.1016/j.ijpharm.2023.12261710.1016/j.ijpharm.2023.122617 ↗
35. 10.1002/smll.20240386910.1002/smll.202403869 ↗
36. 10.1002/advs.20220047710.1002/advs.202200477 ↗